AU2010333039B2 - Pharmaceutical composition for treatment of dry eye syndrome - Google Patents
Pharmaceutical composition for treatment of dry eye syndrome Download PDFInfo
- Publication number
- AU2010333039B2 AU2010333039B2 AU2010333039A AU2010333039A AU2010333039B2 AU 2010333039 B2 AU2010333039 B2 AU 2010333039B2 AU 2010333039 A AU2010333039 A AU 2010333039A AU 2010333039 A AU2010333039 A AU 2010333039A AU 2010333039 B2 AU2010333039 B2 AU 2010333039B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- eye
- ciclosporin
- keratoconjunctivitis sicca
- sfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09015423A EP2335735A1 (en) | 2009-12-14 | 2009-12-14 | Pharmaceutical composition for treatment of dry eye syndrome |
| EP09015423.8 | 2009-12-14 | ||
| PCT/EP2010/069495 WO2011073134A1 (en) | 2009-12-14 | 2010-12-13 | Pharmaceutical composition for treatment of dry eye syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010333039A1 AU2010333039A1 (en) | 2012-07-12 |
| AU2010333039B2 true AU2010333039B2 (en) | 2014-08-28 |
Family
ID=41731659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010333039A Active AU2010333039B2 (en) | 2009-12-14 | 2010-12-13 | Pharmaceutical composition for treatment of dry eye syndrome |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8614178B2 (enExample) |
| EP (2) | EP2335735A1 (enExample) |
| JP (5) | JP5663595B2 (enExample) |
| KR (2) | KR101722039B1 (enExample) |
| CN (1) | CN102652022B (enExample) |
| AU (1) | AU2010333039B2 (enExample) |
| BR (3) | BR122020020872B1 (enExample) |
| CA (2) | CA2941956C (enExample) |
| DK (1) | DK2512515T3 (enExample) |
| ES (1) | ES2449308T3 (enExample) |
| IN (1) | IN2012DN03128A (enExample) |
| MX (1) | MX2012006720A (enExample) |
| PL (1) | PL2512515T3 (enExample) |
| PT (1) | PT2512515E (enExample) |
| WO (1) | WO2011073134A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2764063C (en) | 2009-06-03 | 2019-05-14 | Forsight Labs, Llc | Anterior segment drug delivery |
| KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| EP2714010B1 (en) | 2011-05-25 | 2017-03-01 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
| DK2806886T3 (en) * | 2012-01-23 | 2017-06-06 | Novaliq Gmbh | STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES |
| AU2013314370B2 (en) * | 2012-09-12 | 2017-11-30 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| EP3488847B1 (en) * | 2012-09-12 | 2023-11-08 | Novaliq GmbH | Semifluorinated alkane compositions |
| PL2708228T3 (pl) | 2012-09-12 | 2018-11-30 | Novaliq Gmbh | Kompozycje do przemywania oczu |
| EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
| CA2899206C (en) | 2013-01-24 | 2019-07-09 | Transderm, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| JP6304475B2 (ja) * | 2013-01-31 | 2018-04-04 | ロート製薬株式会社 | 点眼剤 |
| ES2799185T3 (es) | 2013-03-13 | 2020-12-15 | Santen Pharmaceutical Co Ltd | Agente terapéutico para la disfunción meibomiana |
| WO2015011199A1 (en) | 2013-07-23 | 2015-01-29 | Novaliq Gmbh | Stabilized antibody compositions |
| CN105813578A (zh) * | 2013-10-15 | 2016-07-27 | 弗赛特影像5股份有限公司 | 用于增加或减少粘液的制剂和方法 |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| WO2016168141A1 (en) | 2015-04-13 | 2016-10-20 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11013403B2 (en) * | 2015-09-29 | 2021-05-25 | The Regents Of The University Of California | Methods of diagnosing diseases of mucosal surfaces |
| KR102584063B1 (ko) * | 2015-09-30 | 2023-09-27 | 노바리크 게엠베하 | 부분불소화 화합물 |
| EP3495023B1 (en) | 2015-09-30 | 2020-04-22 | Novaliq GmbH | Semifluorinated compounds and their compositions |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| CA3036306C (en) * | 2016-09-23 | 2024-05-14 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP3518921B1 (en) * | 2016-09-28 | 2021-08-11 | Novaliq GmbH | Compositions comprising a cannabinoid receptor binding ligand |
| CA3045733C (en) * | 2016-12-22 | 2024-01-16 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| JP7032404B2 (ja) * | 2016-12-23 | 2022-03-08 | ノバリック ゲーエムベーハー | ドライアイ疾患の治療のための眼科用組成物 |
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| JP7072582B2 (ja) * | 2017-04-21 | 2022-05-20 | ノバリック ゲーエムベーハー | ヨウ素組成物 |
| US10717691B2 (en) | 2017-05-05 | 2020-07-21 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
| WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| US20210346313A1 (en) * | 2018-09-22 | 2021-11-11 | Novaliq Gmbh | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| KR102808092B1 (ko) | 2018-09-27 | 2025-05-22 | 더마리크 테라퓨틱스, 인크. | 지질 장벽 수복 |
| JP7500550B2 (ja) | 2018-10-12 | 2024-06-17 | ノバリック ゲーエムベーハー | 乾性眼疾患の治療のための眼科用組成物 |
| WO2020152046A1 (en) * | 2019-01-21 | 2020-07-30 | Novaliq Gmbh | Pharmaceutical composition for the treatment of ocular neovascularisation |
| WO2020165132A1 (en) | 2019-02-13 | 2020-08-20 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| US20220226426A1 (en) | 2019-05-24 | 2022-07-21 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| EP4025235A1 (en) | 2019-09-06 | 2022-07-13 | Novaliq GmbH | Ophthalmic composition for the treatment of uveitis |
| WO2021048803A1 (en) | 2019-09-13 | 2021-03-18 | Minas Coroneo | Eye drop dispenser |
| US20210308154A1 (en) | 2020-03-24 | 2021-10-07 | Hovione Scientia Limited | Methods and Compositions for Treating Meibomian Gland Dysfunction |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| EP4665377A1 (en) * | 2023-02-13 | 2025-12-24 | Novaliq GmbH | Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease |
| AU2023270196B2 (en) * | 2023-11-20 | 2025-06-26 | Dyer, Gordon Wayne DR | Method of Arthropod Egress |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123035A1 (en) * | 2004-06-08 | 2005-12-29 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE109970T1 (de) | 1987-09-03 | 1994-09-15 | Univ Georgia Res Found | Cyclosporin-augenmittel. |
| US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
| US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| DE19861012A1 (de) * | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| PT1173177E (pt) * | 1999-04-30 | 2005-03-31 | Sucampo A G | Utilizacao de compostos macrolidos para tratamento do olho seco |
| DE19938668B4 (de) * | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| ES2387619T3 (es) * | 2004-04-19 | 2012-09-27 | Centre National De La Recherche Scientifique (Cnrs) | Suplementos de tensioactivos pulmonares |
| DE102007055046A1 (de) * | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
-
2009
- 2009-12-14 EP EP09015423A patent/EP2335735A1/en not_active Withdrawn
-
2010
- 2010-12-13 DK DK10790775.0T patent/DK2512515T3/en active
- 2010-12-13 KR KR1020167023214A patent/KR101722039B1/ko active Active
- 2010-12-13 BR BR122020020872-4A patent/BR122020020872B1/pt active IP Right Grant
- 2010-12-13 US US13/513,886 patent/US8614178B2/en active Active
- 2010-12-13 IN IN3128DEN2012 patent/IN2012DN03128A/en unknown
- 2010-12-13 CA CA2941956A patent/CA2941956C/en active Active
- 2010-12-13 PT PT107907750T patent/PT2512515E/pt unknown
- 2010-12-13 EP EP10790775.0A patent/EP2512515B1/en active Active
- 2010-12-13 ES ES10790775.0T patent/ES2449308T3/es active Active
- 2010-12-13 WO PCT/EP2010/069495 patent/WO2011073134A1/en not_active Ceased
- 2010-12-13 MX MX2012006720A patent/MX2012006720A/es active IP Right Grant
- 2010-12-13 BR BR112012014190A patent/BR112012014190B8/pt active IP Right Grant
- 2010-12-13 JP JP2012542577A patent/JP5663595B2/ja active Active
- 2010-12-13 AU AU2010333039A patent/AU2010333039B2/en active Active
- 2010-12-13 KR KR1020127018066A patent/KR101652714B1/ko active Active
- 2010-12-13 PL PL10790775T patent/PL2512515T3/pl unknown
- 2010-12-13 CA CA2776860A patent/CA2776860C/en active Active
- 2010-12-13 CN CN201080055507.7A patent/CN102652022B/zh active Active
- 2010-12-13 BR BR122017018955-7A patent/BR122017018955B1/pt active IP Right Grant
-
2014
- 2014-10-01 JP JP2014203406A patent/JP6096731B2/ja active Active
-
2016
- 2016-12-22 JP JP2016248533A patent/JP6397472B2/ja active Active
-
2018
- 2018-08-31 JP JP2018163569A patent/JP2019006803A/ja active Pending
- 2018-12-28 JP JP2018248700A patent/JP6731039B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005123035A1 (en) * | 2004-06-08 | 2005-12-29 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010333039B2 (en) | Pharmaceutical composition for treatment of dry eye syndrome | |
| EP3518921B1 (en) | Compositions comprising a cannabinoid receptor binding ligand | |
| CA2788060C (en) | Pharmaceutical composition for treatment of increased intraocular pressure | |
| HK40036791A (en) | Compositions comprising a cannabinoid receptor binding ligand | |
| HK1172269B (en) | Pharmaceutical composition for treatment of dry eye syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |